Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer

BACKGROUND: Breast cancer (BC) is one of the most common malignant tumors in women. In addition, human epidermal growth factor receptor 2-positive (HER2+) BC is overexpressed in 25% of BC patients, resulting in the predicament of poor prognosis. Although first- and second-line treatments have been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Lanqi, Ren, Ning, Zheng, Yu, Yang, Yibei, Xu, Qiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446218/
https://www.ncbi.nlm.nih.gov/pubmed/37621688
http://dx.doi.org/10.3389/fonc.2023.1221969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446218/
https://www.ncbi.nlm.nih.gov/pubmed/37621688
http://dx.doi.org/10.3389/fonc.2023.1221969

Ejemplares similares